Pros
The company promotes from within more than many other pharma companies. Like most pharma companies they have good salaries and benefits. There are some nice people at Biogen. Unfortunately, many have become demoralized and left in the past few years and the rest are planning their exit strategy. Which I guess can provide more opportunities to promote from within, so some will stay hoping it's their chance to move up.
Cons
The company is a sinking ship and doesn't have a solid strategy for its long-term survival. They have trashed goodwill amongst employees by continuing to let the incompetent top tier management steer the ship. The mood in US corporate operations has turned panicked and ugly. Everyone who's smart has already either headed for the lifeboats or is trying to find one to get on. The rest better hope there's a large floating door to get on when the ship goes down. (But don't expect Rose to move over so you can get on it, too.) There should be a shareholder revolt to replace most of the BOD, the CEO and his direct reporting managers. They were fine when they had MS blockbusters filling their pockets but they haven't got a clue what to do now to save the company. They are hoping this deal with Sage will help them hang on until they can fix the other problems and get something else to market. It won't. Unimpressive drug and the typical power struggle that happens with "joint" marketing is likely. Just read what the financial analysts are saying. We have seen this movie before.
